Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

Market Cap	5.17B +9.4%
Revenue (ttm)	917.99M +9.5%
Net Income	168.68M +274.4%
EPS	1.06 +270.4%
Shares Out	157.53M
PE Ratio	30.97
Forward PE	29.04
Dividend	0.35 (1.02%)
Ex-Dividend Date	Jun 9, 2025

Volume	4,455,300
Open	34.19
Previous Close	34.19
Day's Range	32.25 - 34.24
52-Week Range	29.17 - 67.98
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 793
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603590

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.